After positive trial findings for its treatment for liver illness were released, Zealand Pharma’s shares shot up, putting the company in the forefront of the expanding weight-loss medication industry. A new Phase 2 research showed that the medication survodutide was 83% effective in treating “MASH,” a kind of liver inflammation linked to an overabundance of fat cells. On Monday, the business made these encouraging results public.
Currently conducting five Phase-3 trials as part of a clinical programme for overweight and obese adults, the medicine has demonstrated promise efficacy in patients battling with obesity. Moreover, the US Food and Drug Administration has given it fast-track designation.
Following the drug’s safety and effectiveness being shown at the highest dosage level in the most recent trial results, market analysts are excited about the drug’s potential in obesity research.
Source (CNBC)
